Literature DB >> 28401370

The Research on the Relationship of RAGE, LRP-1, and Aβ Accumulation in the Hippocampus, Prefrontal Lobe, and Amygdala of STZ-Induced Diabetic Rats.

Lou-Yan Ma1, Yu-Lang Fei2, Xiao-Ye Wang3, Song-Di Wu4, Jun-Hui Du5, Mei Zhu6, Long Jin1, Ming Li1, Hai-Long Li1, Jia-Jia Zhai1, Lu-Peng Ji7, Ran-Ran Ma8, Song-Fang Liu9, Mo Li1, Li Ma1, Xiao-Rui Ma1, Qiu-Min Qu10, Ya-Li Lv11.   

Abstract

Diabetes mellitus (DM) has been regarded as an important risk factor for Alzheimer's disease (AD), and diabetic patients and animals have shown cognitive dysfunction. More research has shown that the amyloid-β (Aβ), which is a hallmark of AD, was found deposited in the hippocampus of diabetic rats. This Aβ accumulation is regulated by the receptor for advanced glycation end products (RAGE) and low-density lipoprotein receptor-related protein (LRP-1). However, the expression of RAGE and LRP-1 in diabetic rats is not very clear. In the present study, we used streptozotocin (STZ)-induced diabetic rats to investigate whether the expression of RAGE and LRP-1 is related to Aβ1-42 deposition at the hippocampus, prefrontal lobe, and amygdala in DM. We found that diabetic rats had longer escape latency and less frequency of entrance into the target zone than that of the control group (P < 0.05) in the Morris water maze (MWM) test. The Aβ1-42 expression in the hippocampus and prefrontal lobe significantly increased in the DM group compared to the control group (P < 0.05). RAGE increased (P < 0.05), while LRP-1 decreased (P < 0.05) in the hippocampus tissue and prefrontal lobe tissue of DM rats. The Aβ1-42 deposition was correlated with RAGE positively (P < 0.05), but with LRP-1 negatively (P < 0.05). Further, the expression levels of Aβ1-42, RAGE, and LRP-1 were not changed in the amygdala between the diabetic rats and the control group. These findings indicated that upregulating RAGE and/or downregulating LRP-1 at the hippocampus and the prefrontal lobe contributed to the Aβ1-42 accumulation and then further promoted the cognitive impairment of diabetic rats.

Entities:  

Keywords:  Amyloid; Cognition; Diabetes; LRP-1; Rage

Mesh:

Substances:

Year:  2017        PMID: 28401370     DOI: 10.1007/s12031-017-0892-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  47 in total

Review 1.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 2.  Is structural remodeling in regions governing memory an univocal correlate of memory?

Authors:  Martine Ammassari-Teule
Journal:  Neurobiol Learn Mem       Date:  2016-09-15       Impact factor: 2.877

3.  A model of amygdala-hippocampal-prefrontal interaction in fear conditioning and extinction in animals.

Authors:  Ahmed A Moustafa; Mark W Gilbertson; Scott P Orr; Mohammad M Herzallah; Richard J Servatius; Catherine E Myers
Journal:  Brain Cogn       Date:  2012-11-17       Impact factor: 2.310

4.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin.

Authors:  C G Jolivalt; C A Lee; K K Beiswenger; J L Smith; M Orlov; M A Torrance; E Masliah
Journal:  J Neurosci Res       Date:  2008-11-15       Impact factor: 4.164

7.  Dietary advanced glycation end products are associated with decline in memory in young elderly.

Authors:  Rebecca K West; Erin Moshier; Irit Lubitz; James Schmeidler; James Godbold; Weijing Cai; Jaime Uribarri; Helen Vlassara; Jeremy M Silverman; Michal Schnaider Beeri
Journal:  Mech Ageing Dev       Date:  2014-07-15       Impact factor: 5.432

8.  Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice.

Authors:  Li Ping Liu; Hao Hong; Jian Ming Liao; Tong Sheng Wang; Jing Wu; Si Si Chen; Yong Qi Li; Yan Long; Yuan Zheng Xia
Journal:  Synapse       Date:  2009-08       Impact factor: 2.562

Review 9.  Receptor for advanced glycation end products and its involvement in inflammatory diseases.

Authors:  Yaw Kuang Chuah; Rusliza Basir; Herni Talib; Tung Hing Tie; Norshariza Nordin
Journal:  Int J Inflam       Date:  2013-09-11

10.  The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease.

Authors:  J Provias; B Jeynes
Journal:  Int J Alzheimers Dis       Date:  2014-09-18
View more
  3 in total

Review 1.  Potential microRNA-related targets in clearance pathways of amyloid-β: novel therapeutic approach for the treatment of Alzheimer's disease.

Authors:  Soheil Madadi; Heidi Schwarzenbach; Massoud Saidijam; Reza Mahjub; Meysam Soleimani
Journal:  Cell Biosci       Date:  2019-11-12       Impact factor: 7.133

Review 2.  Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?

Authors:  Kee Chan Ahn; Cameron R Learman; Glen B Baker; Charles L Weaver; Phil Sang Chung; Hyung Gun Kim; Mee Sook Song
Journal:  J Korean Med Sci       Date:  2019-12-02       Impact factor: 2.153

3.  Salvianolic Acid B improves cognitive impairment by inhibiting neuroinflammation and decreasing Aβ level in Porphyromonas gingivalis-infected mice.

Authors:  Jianwei Liu; Yiling Wang; Jing Guo; Jinyan Sun; Qinfeng Sun
Journal:  Aging (Albany NY)       Date:  2020-06-09       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.